Health Care & Life Sciences » Pharmaceuticals | AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
107,029.00
52,739.00
15,001.00
26,887.00
65,025.00
5,329
Depreciation, Depletion & Amortization
3,775.00
6,219.00
9,567.00
30.00
-
-
Other Funds
465.00
-
-
-
-
17,481
Funds from Operations
97,809.00
35,671.00
3,128.00
30,130.00
27,541.00
22,810
Changes in Working Capital
13,407.00
19,175.00
18,099.00
936.00
8,377.00
2,216
Net Operating Cash Flow
84,402.00
54,846.00
21,227.00
31,066.00
19,164.00
25,026
Capital Expenditures
3,668.00
12,942.00
22.00
7.00
-
Sale of Fixed Assets & Businesses
-
191.00
1,241.00
-
-
Purchase/Sale of Investments
15,738.00
67,461.00
7,535.00
757.00
10,402.00
Net Investing Cash Flow
12,070.00
54,710.00
6,316.00
764.00
10,402.00
Issuance/Reduction of Debt, Net
7,104.00
827.00
11,612.00
4,885.00
4,900.00
Net Financing Cash Flow
46,998.00
1,018.00
1,126.00
20,292.00
29,419.00
Net Change in Cash
25,308.00
882.00
28,669.00
11,538.00
147.00
Free Cash Flow
88,070.00
67,788.00
21,249.00
31,073.00
19,164.00
Change in Capital Stock
53,637.00
191.00
10,486.00
15,407.00
24,519.00
Exchange Rate Effect
26.00
-
-
-
-

About AVEO Pharmaceuticals

View Profile
Address
One Broadway
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.aveooncology.com
Updated 07/08/2019
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. The company was founded by Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.